BioPharmSignal logoBioPharmSignal

Biotech News

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

Nurix Therapeutics (NRIX)Nurix TherapeuticsPartnership

BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced the closing of its previously announced

Related news

NRIXNurix Therapeutics2026-08-04 05:00 EST

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NRIXNurix Therapeutics2026-07-09 20:01 EST

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

RVMDRevolution Medicines2026-08-10 10:01 EST

Revolution Medicines and BeOne Medicines Announce Clinical Development and Regional Commercialization Collaboration

IDYAIDEAYA Biosciences2026-08-19 10:00 EST

IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer

BMYBMYBristol-Myers Squibb Company2026-07-20 10:59 EST

Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA

KYMRKymera2026-09-01 11:00 EST

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

KYMRKymera2026-07-07 11:00 EST

Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader

KURAKura Oncology2026-09-09 11:00 EST

Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes

GPCRStructure Therapeutics2026-09-08 12:00 EST

Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management

ELVNEnliven Therapeutics2026-08-31 22:05 EST

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

View all latest news

Nurix Therapeutics

Targeted Protein Degradation Nurix Therapeutics develops medicines that use the cell’s ubiquitin-proteasome system to remove disease-causing proteins. Its portfolio includes wholly owned degraders and programs partnered with large pharmaceutical companies. Bexobrutideg Bexobrutideg is an oral BTK degrader being advanced as a potential...

Recent company news

NRIXNurix Therapeutics2026-09-01 12:00 EST

Nurix Therapeutics to Participate in Upcoming September Investor Conferences

NRIXNurix Therapeutics2026-08-20 11:00 EST

Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer

NRIXNurix Therapeutics2026-08-04 11:00 EST

Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader

NRIXNurix Therapeutics2026-08-04 05:00 EST

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NRIXNurix Therapeutics2026-07-21 20:01 EST

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology

Stock data

Close
25.44 USD
Market cap
1.69B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States